

REMARKS

Claims 1 and 3-4 are currently under examination in the Application. Reconsideration is respectfully requested in view of the following remarks.


Applicants thank the Examiner for indicating in the Advisory Action mailed August 13, 2004 that the legend of the previously submitted Figure 2 was illegible. A copy of the Declaration of Dr. Davin Dillon and a clean copy of Figure 2 are submitted herewith for reconsideration. Further, with regard to the samples described in Figure 2, Applicants submit that, with the exception of BT-SCID P7 482, all cells examined were from primary breast tumors, *i.e.* were obtained directly from breast tumors.

The Director is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Applicants respectfully submit that all the claims remaining in the application are now believed allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:tt

Enclosure:

Postcard

Copy of Dillon Declaration with Figures 1 and 2

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

518947_1.DOC